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Abstract
Background: Cancer-Testis Antigens (CTAs) are immunogenic proteins that are poor prognostic markers in non-small cell
lung cancer (NSCLC). We investigated expression of CTAs in NSCLC and their association with response to chemotherapy,
genetic mutations and survival.
Methods:We studied 199 patients with pathological N2 NSCLC treated with neoadjuvant chemotherapy (NAC; n= 94), post-
operative observation (n= 49), adjuvant chemotherapy (n= 47) or unknown (n= 9). Immunohistochemistry for NY-ESO-1,
MAGE-A and MAGE-C1 was performed. Clinicopathological features, response to neoadjuvant treatment and overall survival
were correlated. DNA mutations were characterized using the Sequenom Oncocarta panel v1.0. Affymetrix data from the
JBR.10 adjuvant chemotherapy study were obtained from a public repository, normalised and mapped for CTAs.
Results: NY-ESO-1 was expressed in 50/199 (25%) samples. Expression of NY-ESO-1 in the NAC cohort was associated with
significantly increased response rates (P= 0.03), but not overall survival. In the post-operative cohort, multivariate analyses
identified NY-ESO-1 as an independent poor prognostic marker for those not treated with chemotherapy (HR 2.61, 95% CI
1.28–5.33; P= 0.008), whereas treatment with chemotherapy and expression of NY-ESO-1 was an independent predictor of
improved survival (HR 0.267, 95% CI 0.07–0.980; P= 0.046). Similar findings for MAGE-A were seen, but did not meet
statistical significance. Independent gene expression data from the JBR.10 dataset support these findings but were
underpowered to demonstrate significant differences. There was no association between oncogenic mutations and CTA
expression.
Conclusions: NY-ESO-1 was predictive of increased response to neoadjuvant chemotherapy and benefit from adjuvant
chemotherapy. Further studies investigating the relationship between these findings and immune mechanisms are
warranted.
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Background
Although the overall incidence of non-small cell lung cancer
(NSCLC) appears to be declining in North America, mortality has
only recently plateaued [1]. More deaths are attributable to
NSCLC than any other cancer [1]. As symptoms occur late, the
majority of patients are diagnosed with locally advanced or
metastatic disease. Management of late-stage disease has evolved
to include molecular sub-typing for somatic mutations and gene
rearrangements. Unfortunately the rapid translation of molecular
information into the adjuvant and neoadjuvant settings has yielded
conflicting and confusing results. For example, mutations in the
epidermal growth factor receptor (EGFR) gene are clearly
predictive of response to tyrosine kinase inhibitors and improved
survival for metastatic patients. In locally advanced disease,
however, two underpowered studies failed to reproduce this
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observation, and it remains unclear whether tyrosine kinase
inhibitors are beneficial for early stage NSCLC [2,3].
There is currently no consensus for the management of locally
advanced (Stage IIIA) NSCLC. This remains controversial
because of variations in staging techniques, conflicting trial results
and idiosyncratic practices among different institutions [4].
Options include surgery followed by adjuvant chemotherapy
(ACT), neoadjuvant chemotherapy (NAC) followed by surgery and
definitive chemo-radiation alone or followed by surgery. To date,
the only modality shown to significantly improve survival is
surgical resection followed by ACT, as shown in a number of large
studies [5]. Although initial studies of NAC appeared promising,
enthusiasm diminished as more data from large adjuvant studies
became available, leading to poor recruitment and underpowered
analyses [6]. Only one study compared NAC to ACT and
demonstrated equivalency in patients with early stage disease [7],
although there were caveats [4].
One particular rationale for using NAC as opposed to post-
operative adjuvant therapy, is that it provides valuable, potentially
predictive information, based on drug sensitivity in vivo. In contrast
current predictive markers, cannot determine whether an individ-
ual with NSCLC will respond to a given treatment [8]. This is
important as response to treatment can improve resectability and
may translate into improvement in survival [9]. Furthermore, the
ability to predict a priori which patients will benefit makes it
possible to optimize therapy and avoid unnecessary toxicity in
those who are unlikely to respond.
Cancer-Testis antigens (CTAs) are molecules characterized by
expression restricted to normal testis tissue but aberrant expression
in a variety of cancer types, including 10–50% of NSCLC [10,11].
Their expression is often coordinated [12] and associated with
poorer clinical outcome [13] and advanced disease [14,15]. There
is some evidence that they are functional; short interfering RNA
screening of a lung cancer cell line showed that several CTAs were
associated with resistance to paclitaxel chemotherapy [16].
However, the CTAs identified in these screens have not been
extensively studied and their presence in patient lung tumors has
yet to be evaluated. The association with chemoresistance is
analogous to observations in other tumor types where it has been
speculated that CTAs mark more primitive, ‘‘stem-like’’ cells
[10,17–19]. Indeed the current study was initially undertaken in
order to assess the relationship between these antigens and
chemoresistance. It therefore came as a surprise to discover that
NY-ESO-1 and to a lesser extent MAGE-A3 were associated with
chemosensitivity.
While the functional role of CTAs in cancer remains unclear,
the immunogenicity of these molecules has been well documented
[10]. Indeed CTAs were originally identified by cloning antigens
that activated cytotoxic T lymphocytes and screening patient sera
for immunoreactive antibodies [20]. To date over 100 distinct
CTA families have been identified [21] with approximately 30
encoded by genes located on the X-chromosome (CT-X genes).
The promoter regions for all studied CT-X genes contain CpG
islands and are often methylated in somatic tissues and therefore
not expressed. In cancer, global demethylation of the X-
chromosome including the promoter regions of CT-X genes are
believed to result in the coordinated activation of multiple CTAs
[10], although it is unclear whether the CTAs are bystanders or
functionally participate in tumorigenesis.
To evaluate the relationship between chemosensitivity and CTA
expression in NSCLC, we performed immunohistochemical
studies on tumors from patients with pathological N2 (pN2) nodal
involvement (at least Stage IIIA). We investigated two clinical
cohorts, a pre-operative and post-operative cohort. Patients had
either undergone pre-operative NAC, where we investigated the
mediastinal nodal tissue prior to treatment or were treated
surgically with or without adjuvant chemotherapy in the post-
operative group; where we investigated the primary tumor tissue
post-resection. Here we demonstrate that the CTA NY-ESO-1 is
prognostic for poor clinical outcome, however also appears to be
predictive for improved response and survival benefit from
chemotherapy.
Materials and Methods
Patients and clinical specimens
Under a protocol approved by the ethics committees of Austin
Health, St Vincent’s Hospital and Weill Cornell Medical Centre
hospitals, patients who underwent pre-operative NAC or surgery
with or without ACT for pN2 disease were identified and clinical
information captured retrospectively. Consent for accessing tissues
and clinical records was waived on the proviso that patient details
were de-identified. NAC patients were treated with at least three
cycles of platinum-based chemotherapy prior to surgery. ACT
patients were treated with four cycles of platinum-based chemo-
therapy post resection. Patients who did not receive ACT were
observed without any further treatment. For the pre-operative
cohort, samples obtained from mediastinal lymph node sampling
prior to chemotherapy administration were used for CTA staining
and DNA isolation. In the post-operative cohort, the primary
surgical lung tumor specimen was used. Response to NAC was
defined pathologically by down-staging of the initial lesion post-
operatively. Patients were staged pre-operatively with PET scans
or mediastinoscopy.
For further validation we investigated patients treated as part of
the BR.10 study [22] whose tumors were subjected to molecular
profiling using Affymetrix arrays. The original study randomized
482 patients to either receive adjuvant chemotherapy or observa-
tion following surgical resection, however only 133 of these
samples were available for gene expression arrays [23].
CT antigen staining
For CTA staining, 4-mm sections of formalin-fixed paraffin-
embedded (FFPE) tissues were cut and stained as previously
described [19]. NY-ESO-1 (E978) was obtained from the Ludwig
Institute for Cancer Research and used at a concentration of
2.5 mg/mL. MAGE-A antibody (6C1) was purchased from Abcam
and used at 0.3 mg/mL. MAGE-C1/CT7 antibody (CT7-33) was
obtained from Santa-Cruz (cat no sc-20034) and used at 0.5 mg/
mL. The detection of nuclear and/or cytoplasmic staining in any
percentage of tumor cells was considered positive. Complete
absence of staining was considered negative for each CTA tested.
Testis tissue was used as a positive control; normal lung tissue and
absence of primary antibody were used as negative controls.
Mutational Profiling
DNA was isolated from FFPE blocks or unstained slides. For
tumor blocks, an H&E slide was reviewed histologically and
1.5 mm cores were taken from the corresponding block in areas of
high tumor cellularity. For slides, areas of high tumor cellularity
were scraped from the slide. The tissue or core was then de-
paraffinized by serial passages in xylene and alcohol, DNA isolated
using DNeasy blood and tissue kits (Qiagen, Melbourne, Australia)
and subjected to mutational profiling using Sequenom’s MassAr-
ray platform, Oncocarta Panel v1.0, as previously described [24].
This platform interrogates 238 mutations across 19 oncogenes
(http://www.sequenom.com/sites/genetic-analysis/applications/
somatic-mutation-profiling.
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Microarray Analysis
CTA mRNA abundances were evaluated in the BR.10 dataset
[23]. These data are publically available at the National Centre for
Biotechnology Information Gene Expression Omnibus
(GSE14814) and from the Director’s Challenge Project [25].
These analyses were performed in R (v2.14.2). Data pre-
processing was performed using RMA [26] (Affymetrix package
version 1.20.0) and updated Entrez GeneID annotation [27]
(hgu133ahsentrezgcdf package v14.1.0). CTA’s were matched to
the gene expression microarray platform via their Entrez
GeneIDs. Each gene was used to median dichotomize the patient
cohort. Differences in survival between the two groups were
assessed with Kaplan-Meier survival curves and Cox proportional
hazard ratio modeling followed by the Wald test (survival package
v2.36-12) in the whole cohort, patients treated with ACT and
patients not treated with ACT.
Statistics
Differences in patient demographics for CTA positive and CTA
negative patient groups were assessed with x2-tests. A p-value
,0.05 was considered significant. In addition, to evaluate
prognostic and predictive value of CTA expression both univariate
and multivariate Cox proportional hazard ratio modeling analyses
were performed in R (v2.14.2, survival package v2.36-12).
Results
Patients
Clinicopathological data were available for 199 patients in two
cohorts. The first, a pre-operative cohort, included 94 patients
who underwent neoadjuvant chemotherapy followed by surgery.
In the second, a post-operative cohort, 105 patients were included;
49 who had surgical resection alone, 47 who received additional
adjuvant chemotherapy and 9 where adjuvant chemotherapy data
was not recorded. The clinical information for each group is
summarized in Table 1. Patients treated with NAC who
proceeded to surgery represent a highly selected subgroup based
mainly on resectability and good performance status post-
chemotherapy. In the post-operative cohort, patients who did
not receive chemotherapy were mainly treated prior to 2004 when
adjuvant treatment was more broadly accepted.
CT Antigen expression
NY-ESO-1 stained similar proportions in each cohort, with 24/
94 (26%) of pN2 nodes in the pre-operative cohort and 26/105
(25%) of resected lung tumors in the post-operative cohort
(Figure 1). The median age of patients whose tumors stained
positive for NY-ESO-1 was 62 years in the pre-operative and 66
years in the post-operative cohort, which were similar to patients
with NY-ESO-1 negative tumors. More males were NY-ESO-1
positive in both cohorts with 14/24 (58%) positive in the pre-
operative cohort (Px2 = 0.728) and 16/26 (62%) in the post-
operative cohort (Px2 = 0.605).
MAGE-A expression was observed in only 27/94 (29%) pre-
operative patients but in 52/105 (50%) in the post-operative
cohort (Px2 = 0.004). MAGE-C1 stained fewer samples, with 13/
94 (13%) in the NAC cohort but 32/105 (44%) in the post-
operative cohort.
CTAs were expressed in both adenocarcinoma and squamous
cell carcinomas (Figure 1E, 1F). However more squamous cell
carcinomas were positive in both datasets, although this did not
reach statistical significance in the pre-operative cohort. For NY-
ESO-1 in the pre-operative cohort 8/22 (36%) squamous cell
carcinomas were positive compared to 9/60 (15%) adenocarcino-
mas (Px2 = 0.070). Similarly in the post-operative cohort 12/30
(30%) were positive compared to 8/59 (14%; Px2 = 0.011)
adenocarcinomas. These histological differences in CT antigen
staining were similar for MAGE-A and MAGE-C1 and to that
previously reported [13]. Furthermore expression of one CTA was
often associated with expression of the others a phenomenon
which has also been previously observed [13].
Genetic mutations and CT antigen expression
We next sought to determine if CTA expression was associated
with specific genetic mutations. We screened 238 somatic
mutations in 19 oncogenes using Sequenom’s OncoCarta panel
v1.0. Lower rates of mutations in the pre-operative cohort to that
expected in a Caucasian NSCLC population were observed, with
only four EGFR (4%) mutations and nine KRAS (9%) mutations, all
occurring in adenocarcinomas as expected. Two additional cases
harbored BRAF mutations, while three had TP53 mutations and
one an NRAS mutation. The low rates of EGFR and KRAS
mutations may reflect a higher rate of false-negative results due to
the low tumor cell percentage in proportion to non-neoplastic cells
in these lymph nodes, although areas of high tumor cellularity
were specifically selected for DNA isolation. In the post-operative
cohort, rates of mutations were significantly higher, and closer to
those expected for late-stage NSCLC, with 16 EGFR mutations
(15%) and 18 (17%) KRAS mutations. CTA expression was not
associated with oncogenic mutations in adenocarcinomas
(Figure 1E).
Response to neoadjuvant chemotherapy
Response to NAC was assessed based on pathological down
staging. Of the 24 NY-ESO-1 positive tumors, two patients
achieved a complete response (CR; i.e. no residual tumor was
pathologically detectable), 14 a partial response (PR), six had
stable disease (SD) and two progressed through chemotherapy
(PD). In the 70 NY-ESO-1 negative patients, there was one CR,
23 PRs, 36 SD, nine PDs and one missing response (Figure 2).
There was a significantly increased response rate (CR+PR) in NY-
ESO-1 expressing tumors compared to NY-ESO-1 negative ones
(Px2 = 0.034).
Despite improved responses to NAC, no survival differences
were observed in patients expressing NY-ESO-1 or any other
CTA compared to those tumors that did not. Pathological CR was
associated with prolonged survival; however, for the majority of
patients, the best response was a PR. It should be noted that
patients that were known to have progressed through chemother-
apy pre-operatively and therefore unable to proceed to surgery
were not included in this study. Furthermore given the low rate of
NY-ESO-1 expression, these analyses were underpowered to
detect a survival difference.
Survival following adjuvant chemotherapy
The improved responses to NAC in patients with pN2 NSCLC
expressing NY-ESO-1 led us to investigate a post-operative cohort
of patients with occult N2 disease, half of whom received
chemotherapy in the adjuvant setting. Of 105 patients in the
post-operative cohort, the use of adjuvant chemotherapy was
unable to be determined in nine, leaving 96 patients for whom
survival was correlated with CTA expression. Expression of
MAGE-A and/or NY-ESO-1 was associated with poorer survival
than MAGE-A negative or NY-ESO-1 negative tumors. MAGE-
C1 expression was not associated with poorer outcome. Treatment
with chemotherapy however resulted in significantly improved
survival especially in NY-ESO-1 expressing tumors (Figure 3). In
multivariate analysis NY-ESO-1 expression remained an inde-
Cancer-Testis Antigens as Biomarkers in NSCLC
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pendent poor prognostic factor (HR 2.61, 95% CI 1.28–5.33;
p = 0.008 Wald test) whereas treatment with chemotherapy and
expression of NY-ESO-1 was an independent predictor of
improved survival (HR 0.267, 95% CI 0.073–0.980; p= 0.046
Wald test. Table 2).
Survival in an independent cohort using gene expression
data
We sought to validate our findings using microarray data
previously published from the BR.10 adjuvant chemotherapy
dataset [23]. This cohort contained Affymetrix microarray data for
the mRNA abundances of 133 patients of which 71 received
adjuvant chemotherapy. Unfortunately, although oligonucleotide
probes representing MAGE-A1, MAGE-A4 and MAGE-C1 could
be mapped to the array, NY-ESO-1 was not present after mapping
to modern gene-annotations. Expression of MAGE-A1 and 4
antigens was associated with inferior survival in patients random-
ized to observation. However MAGE-A1 and 4 positive patients
treated with chemotherapy had improved survival compared to
similarly treated MAGE-A1 and 4 negative patients and survival
curves similar to those seen in our post-operative cohort of patients
were observed (Figure 4). However, these differences in survival
did not reach the level of statistical significance. It is important to
note that although survival in the overall BR.10 dataset
demonstrated statistically significant differences for patients treated
with adjuvant chemotherapy, in this subset of 133 patients, the
trend toward improved survival remained, however was not
significant. This may explain why in this underpowered cohort,
similar trends were seen to those observed in our post-operative
cohort although did not reach the level of statistical significance.
Discussion
These data provide further confirmation that CTA expression
in NSCLC is associated with poor overall prognosis. In particular
NY-ESO-1 was associated with significantly poorer outcome in
patients not treated with adjuvant chemotherapy when compared
Table 1. Clinicopathological features associated with CTA expression in two cohorts of patients.
Pre-operative cohort (n=94) Post-operative cohort (n =105)
Age median (range) 63 (37–82) Age median (range) 66 (29–86)
Sex Sex
Male 50 Male 58
Female 44 Female 47
Stage Stage
IIB 3 IIIA 99
IIIA 88 IIIB 6
IIIB 3
Histology Histology
Adenocarcinoma 60 Adenocarcinoma 59
Squamous 22 Squamous 30
Other 11 Other 16
NA 1
Response Adjuvant chemo
Complete Response (CR) 3 No 49
Partial Response (PR) 37 Yes 47
Stable Disease (SD) 42 NA 9
Progressive Disease (PD) 11
NA 1
NY-ESO-1 NY-ESO-1
2 70 2 79
+ 24 + 26
MAGE-A MAGE-A
2 67 2 53
+ 27 + 52
MAGE-C1 MAGE-C1
2 81 2 73
+ 13 + 32
Mutation status (EGFR/KRAS/TP53) Mutation status (EGFR/KRAS/TP53)
2 62 2 50
+ 25 + 50
NA 7 NA 5
doi:10.1371/journal.pone.0067876.t001
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to NY-ESO-1 negative patients who were also not treated with
adjuvant chemotherapy. Although similar trends were seen for
MAGE-A and MAGE-C1, NY-ESO-1 remained the strongest
predictor of response to chemotherapy in the neoadjuvant setting
but also for benefit from adjuvant chemotherapy. These findings
support NY-ESO-1 as a useful prognostic factor but also a
potential predictive factor for significant benefit from adjuvant and
neoadjuvant chemotherapy.
Despite the improved responses to chemotherapy in the
neoadjuvant setting it was surprising that no translation from
response into a survival benefit was observed for patients with NY-
ESO-1+ tumors. However it should be emphasized that these
analyses were underpowered to detect a survival difference. These
results paralleled similar findings in patients treated with
neoadjuvant chemotherapy in breast cancer. Breast tumors that
were negative for estrogen receptor, progesterone receptor and
HER2 gene amplification, otherwise known as ‘‘triple negative’’
breast cancers also strongly expressed CT-X antigens [28,29]
compared to receptor-positive tumors. Furthermore, triple nega-
tive breast cancers have been shown to be more chemosensitive to
anthracycline and platinum based chemotherapy [30,31]. Inter-
estingly, however, although response to chemotherapy was
significantly improved in triple negative tumors, survival was not
impacted in these studies, except in the minority of patients who
achieved a complete response. This led to the hypothesis that the
poorer phenotype associated with CTA expression and triple
negativity resulted in increased relapse rates, despite good initial
responses [31]. These findings may explain why patients in our
study whose tumors expressed NY-ESO-1 had significantly
improved responses to neoadjuvant chemotherapy and yet no
survival benefit when compared to patients with NY-ESO-1
negative tumors.
One caveat to our study is that the tissue investigated for our
two cohorts were different, with the pre-operative cohort
consisting of lymph node tissue and the post-operative cohort
the primary lung tumor. There were clear differences in the
number of samples that were positive for CTAs as well as for
mutations between these cohorts. However in patients undergoing
Figure 1. CTA expression by IHC in an individual patient tumor sample. A: Testis (positive control), B: NY-ESO-1, C: MAGE-A, D: MAGE-C1, E:
Heat map detailing overlap in expression of CTAs and other clinicopathological features in the neoadjuvant cohort.
doi:10.1371/journal.pone.0067876.g001
Figure 2. Expression of N-ESO-1 and response to neoadjuvant chemotherapy (A). CR=Complete Response, PR= Partial Response,
SD= Stable Disease, PD=Progressive Disease, NA=Not Assessable. Forest plot detailing factors associated with survival in patients who were treated
in the post-operative cohort. Sq = Squamous Cell, ADC=Adenocarcinoma, ACT=Adjuvant Chemotherapy (B).
doi:10.1371/journal.pone.0067876.g002
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neoadjuvant chemotherapy, it is not possible to obtain a large
portion of the primary tissue and using tissue post-chemotherapy
may also be inaccurate. In our study we also tested the primary
lung tumor sample after NAC for NY-ESO-1. In samples with
viable tumor, NY-ESO-1 expression was not seen in the primary
resected tumor if the pre-treatment lymph node was negative;
however in 13 cases, despite NY-ESO-1+ lymph nodal tissue,
following chemotherapy NY-ESO-1 expression was not detected
in the primary resected tumor (data not shown).
As the functional role of CTAs is poorly understood, it is
difficult to define a mechanism by which their expression could
influence chemosensitivity. Whilst some data exist supporting
KRAS mutations as a marker of chemoresistance and EGFR
mutations as a marker of chemosensitivity [8], our data do not
demonstrate an association between these mutations and NY-
ESO-1 expression. Certainly our findings are in contradistinction
to recent studies demonstrating that in cell lines, other CTAs
including acrosin-binding protein (ACRBP) were associated with
resistance to taxane chemotherapy [16]. However, unlike ACRBP
which is a non-X-CTA with a specific function associated with the
mitotic spindle [32], CT-X antigens evaluated in his study have no
well-defined function to date. This difference likely underlies their
different influences on chemosensitivity. Other studies have
demonstrated that the MAGE proteins form complexes with
Kap-1, a known co-repressor of TP53 and MAGE may thus act to
prevent cells from undergoing apoptosis and promote tumorigen-
esis. However, linking these pathways to explain the improved
response to chemotherapy in breast and now lung cancer warrants
further investigation.
As CTAs are known to be immunogenic, it is perhaps more
plausible that the improved response and survival for patients
whose tumors express NY-ESO-1 were not the result of increased
cytotoxicity, but rather were mediated through immunological
mechanisms. NY-ESO-1 is a potent stimulator of T-Cells and has
been used as a tumor vaccine in a variety of tumor types [21,33]
Chemotherapy induced tumor cell lysis could enable antigens
previously ignorant to T-Cells to be processed and presented via
antigen presenting cells with resultant T-Cell stimulation. This
may explain in part the increased down-staging of tumors in the
short term, although one would expect a T-Cell response to result
in more durable remissions. Evidence for this is supported by
recent studies investigating immune checkpoint inhibitors where
the impact of immune activation can be delayed such that initial
disease progression may be observed followed by more durable
remissions [34]. Interestingly, NY-ESO-1 specific T cell responses
have been reported to increase in frequency and functionality
during anti-CTLA-4 treatment, an immune checkpoint inhibitor,
with resultant durable disease remissions, therefore highlighting
the importance of this antigen [35]. Previous studies have not
shown a correlation between the development of antibodies to
tumor antigens and spontaneous remissions. However in the
context of chemotherapy, immunological recognition and re-
sponse in addition to chemotherapy induced depletion of
regulatory T-Cells could explain the improved response rates we
have observed and the longer-term survival advantage in the
adjuvant setting. An alternative to these hypotheses is that the
survival advantage seen in the adjuvant setting may not represent
improved tumor responses but poorer survival in the absence of
chemotherapy. Further studies are warranted to better explain our
findings.
Recent clinical trials investigating immune checkpoint inhibitors
in NSCLC have demonstrated significant promise particularly in
squamous cell carcinomas [36,37]. A study investigating a
monoclonal antibody directed against CTLA-4, a molecule that
inhibits T-Cell activation, demonstrated an overall benefit in
Figure 3. Survival curves demonstrating NY-ESO-1 to be a poor prognostic factor (A) and a predictive marker for benefit from
adjuvant chemotherapy (B).
doi:10.1371/journal.pone.0067876.g003
Table 2. Multivariate analysis of factors associated with
survival in patients treated with surgery initially.
HR 95% CI P (Wald test)
Stage (IIIB vs. IIIA) 1.245 0.4697–3.299 0.660
Histology (SQ vs. ADC) 1.542 0.8445–2.816 0.159
Histology (other vs. ADC) 1.331 0.5561–3.185 0.521
ACT 0.7427 0.3977–1.387 0.351
NY-ESO-1 2.609 1.278–5.329 0.008
NY-ESO-1:ACT 0.2674 0.07301–0.9795 0.046
HR= hazard ratio, ACT = adjuvant chemotherapy, SQ= squamous cell,
ADC= adenocarcinoma histology.
doi:10.1371/journal.pone.0067876.t002
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prolonging immune related progression free survival. Although
tumors of all different histological types appeared to benefit, a
trend towards improved benefit was seen in patients with
squamous cell histology, a subgroup that we have also observed
to highly express CTAs [36]. These data have resulted in the
launch of a randomized phase III study comparing the addition of
ipilimumab to chemotherapy in patients with squamous cell
histology. Similarly an inhibitor of programmed death-1 (PD-1), a
molecule also involved in T-cell inhibition, has recently demon-
strated efficacy in a Phase I study [37]. Significantly more
responses were observed in patients with squamous cell carcinoma
when compared to non-squamous tumor types. Although we are
currently unable to demonstrate that CTAs play a role in these
early studies, the strong association of these immunogenic
molecules with the same histology to benefit from immunoactiva-
tion warrants further investigation.
These data demonstrate that expression of the CTA NY-ESO-1
is associated with increased downstaging with chemotherapy given
in the neoadjuvant setting and significant survival benefit with
chemotherapy given in the adjuvant setting. Our data therefore
support NY-ESO-1 as both a (poor) prognostic marker and also a
predictive marker. As the assay is straightforward and easy to
interpret, NY-ESO-1 could easily be studied prospectively as a
marker. Perhaps more importantly, the immunogenicity of this
molecule may be a rationale for future studies using NY-ESO-1 as
a therapeutic target, thereby better personalizing treatment
towards those most likely to derive benefit.
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